Danish pharmaceutical giant Novo Nordisk reported better-than-expected net profit for the fourth quarter, driven by strong demand for its Wegovy obesity drug. While sales of Wegovy slightly missed estimates, the company's overall sales increased by 30% in the fourth quarter. Novo Nordisk also anticipates a slowdown in sales growth for 2025, citing intensifying competition and pricing pressure in the diabetes and obesity care market.
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
The drug maker posted a 107% year-on-year increase in Wegovy sales to 19.87 billion Danish kroner in the three months to the end of December, slightly missing estimates.rose on Wednesday after the company reported better-than-expected net profit in the fourth quarter amid soaring demand for its Wegovy obesity drugs, but forecast a slight slowdown in sales for 2025.Net profit at the Danish pharmaceutical behemoth rose 29% annually to 28.
Overall sales at the company — which also produces diabetes and rare disease treatments — increased 30% in the fourth quarter and 26% on the year at constant exchange rates. That growth was driven primarily by demand from the North America and Europe, Middle East and Africa regions.Novo Nordisk, however, forecast slower sales growth for 2025 of between 16% to 24% at constant exchange rates, below the 18% to 26% forecast for 2024.
"A further acceleration will depend on more expanded use cases being approved by health regulators," she added.
NOVO NORDISK WEGOVY OBESITY DRUGS PHARMACEUTICAL INDUSTRY SALES GROWTH
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk Surpasses Expectations with Wegovy Sales, CagriSema Trial Results UnderwhelmDanish pharmaceutical giant Novo Nordisk reports strong fourth-quarter earnings driven by soaring demand for its obesity drug Wegovy. While Wegovy sales exceeded expectations, late-stage trial results for experimental obesity drug CagriSema fell short, raising questions about its future potential.
Read more »
Novo Nordisk posts net profit beat on Wegovy sales jump, sees growth slowdown this yearDanish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.
Read more »
US to Negotiate Prices for Novo Nordisk's Ozempic and WegovyThe US government plans to negotiate lower prices for Novo Nordisk's popular weight loss and diabetes drugs, Ozempic and Wegovy, as part of a broader effort to reduce drug costs for Medicare. This move comes as the company faces other challenges, including disappointing clinical trial results and investigations into potential side effects.
Read more »
Novo Nordisk's Higher-Dose Semaglutide Shows Promising Results in Obesity TrialA new study by Novo Nordisk shows that a 7.2 milligram dose of semaglutide leads to significant weight loss in individuals with obesity, exceeding the effects of currently available semaglutide-based medications.
Read more »
Crypto Stocks Soar Amid Trump Executive Order Rumors, While Novo Nordisk and J.B. Hunt Face DownturnsThis article highlights the midday trading performance of various companies, focusing on the surge in crypto-related stocks due to reports of a potential executive order by President-elect Donald Trump, the decline in Novo Nordisk's share price after its drug semaglutide was included in Medicare's price negotiation list, and the drop in J.B. Hunt's stock after missing fourth-quarter earnings expectations. It also covers the gains in Qorvo, MoonLake Immunotherapeutics, Lam Research, Applied Materials, and Life360, along with Intel's significant rise amidst takeover speculation.
Read more »
Stocks to Watch Before the Bell: SolarEdge, Novo Nordisk, AMD, Carvana, and MoreGet the latest pre-market stock movers, including SolarEdge, Novo Nordisk, Advanced Micro Devices, Carvana, and more.
Read more »